Table 2.

Univariate analysis of clinical outcome for the study population according to Bcl-6 expression and induction treatment

	CHOP			R-CHOP
Clinical outcome	Bcl-6+	Bcl-6-	P*	Bcl-6+	Bcl-6-	P*
No. of patients	68	24	NA	86	21	NA
Objective response, CR + PR, no. (%)	51 (75)	19 (79)	.8	70 (81)	18 (86)	.8
2-y survival including MR, %†
FFS	61 ± 6	38 ± 10	.004	64 ± 5	75 ± 10	.6
OS	73 ± 5	42 ± 10	.001	74 ± 5	76 ± 9	.7
2-y survival, removing effect of MR, %‡
FFS	54 ± 6	9 ± 6	< .001	58 ± 6	76 ± 9	.2
OS	77 ± 5	17 ± 8	< .001	71 ± 5	79 ± 8	.2

Median follow-up among all patients is 3.4 years.

NA indicates not applicable.

^*P values are from the Fisher exact test for objective response rate and log-rank test for FFS and OS.

^†Analysis includes patients who were randomized to receive MR. Value is 2-year estimated percent ± the SE of the 2-year estimate.

^‡Analysis removes the effect of MR on induction comparison and obtains an unbiased effect of induction treatment. Value is 2-year estimated percent ± the SE for the 2-year estimate.